8 completed. 8 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
| Phase 1 | 2 | Completed 2 |
Follow cenegermin: new trials by email Literature Review of cenegermin trials Research Report on cenegermin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease. rhNGF 5 μg/mL, rhNGF 10 μg/mL, Vehicle (Placebo solution) - Dry Eye Disease | Phase 2 | Completed | Dompé Farmaceutici S.p.A | 317 | 2024-01-22 | 2026-02-13 |
| A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye rhNGF 20 μg/ml, rhNGF 20 μg/ml + vehicle, Vehicle - Dry Eye Syndrome | Phase 2 | Completed | Dompé Farmaceutici S.p.A | 261 | 2019-06-10 | 2024-04-19 |
| An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye NGF, Vehicle - Dry Eye | Phase 2 | Completed | Dompé Farmaceutici S.p.A | 150 | 2017-01-20 | 2019-02-08 |
| Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema rhNGF 180 µg/ml eye drops solution, vehicle eye drops - Retinitis Pigmentosa, Cystoid Macular Edema | Phase 2 | Completed | Ospedale San Raffaele | 45 | 2015-05-01 | 2017-09-06 |
| Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK rhNGF 20µg/ml, Placebo - Neurotrophic Keratitis | Phase 2 | Completed | Dompé Farmaceutici S.p.A | 48 | 2015-02-01 | 2022-12-08 |
| Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye rhNGF 20 µg/mL, rhNGF 4 µg/mL - Dry Eye Syndrome | Phase 2 | Completed | Dompé Farmaceutici S.p.A | 40 | 2014-01-20 | 2024-04-19 |
| A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP) rhNGF 60 µg/ml eye drops solution, rhNGF 180 µg/ml eye drops solution, Placebo - Retinitis Pigmentosa | Phase 1 / Phase 2 | Completed | Dompé Farmaceutici S.p.A | 50 | 2014-01-01 | 2024-04-18 |
| Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis. rhNGF 10 μg/ml, rhNGF 20 μg/ml, vehicle - Neurotrophic Keratitis, Keratitis | Phase 1 / Phase 2 | Completed | Dompé Farmaceutici S.p.A | 174 | 2013-01-01 | 2024-04-19 |
Dry Eye Syndromes (4) · Retinitis Pigmentosa (2) · Cone-Rod Dystrophies (1) · Corneal Ulcer (1) · Keratitis (1) · Macular Edema (1)
Dompé Farmaceutici S.p.A (7) · Ospedale San Raffaele (1)
Italy (4) · United States (4) · Austria (1) · France (1) · Germany (1) · Poland (1) · Spain (1) · United Kingdom (1)
Flavio Mantelli, MD, PhD (4) · Francesco Sinigaglia, MD (1) · Giacomina Massaro Giordano, MD (1) · Paolo Rama, MD (1) · William Lipsky, MD (1)
PMID 26448169, PMID 30944103, PMID 39020305
2023 (1)